Clifutinib

DRUG2 trials

Sponsors

Sunshine Lake Pharma Co., Ltd.

Conditions

Healthy Adult SubjectLeukemia, Acute Myeloid (AML)

Phase 1

A Single-center, Randomized, Open-label, Parallel-design Clinical Study to Evaluate the Pharmacokinetic Effects of Itraconazole, Fluconazole or Efavirenz on a Single Dose of Clifutinib in Healthy Participants

Not yet recruitingNCT07341672

Sunshine Lake Pharma Co., Ltd.Healthy Adult Subject

Start: 2026-12-31End: 2027-05-08Target: 80Updated: 2026-04-27

Phase 3

HEC73543 Versus Salvage Chemotherapy in R/R FLT3-ITD AML

RecruitingNCT05586074

Sunshine Lake Pharma Co., Ltd.Leukemia, Acute Myeloid (AML)

Start: 2023-03-03End: 2028-05-30Target: 324Updated: 2026-04-28

Related Papers

Discovery of FLT3-ITD Inhibitor Clifutinib: A Novel Biphenylacetylene Urea Derivative in Clinical Trials for the Treatment of Relapsed/Refractory FLT3-ITD<sup>+</sup> Acute Myeloid Leukemia

Journal of Medicinal Chemistry2025-04-115 citations

Discovery of FLT3-ITDInhibitor Clifutinib: A NovelBiphenylacetylene Urea Derivative in Clinical Trials for the Treatmentof Relapsed/Refractory FLT3-ITD<sup>+</sup> Acute Myeloid Leukemia

OPAL (Open@LaTrobe) (La Trobe University)2025-04-11

Efficacy and Safety of Clifutinib, a Novel, Highly Selective, Oral FLT3 Inhibitor, in Patients with FLT3-Mutated Relapsed or Refractory Acute Myeloid Leukemia：Updated Results from a Phase I Study

Blood2023-11-022 citations